Semaglutide, a GLP-1 drug, aids diabetes and obesity by controlling glucose and appetite Patent expiry from March 20, 2026, will allow generic, more affordable versions of semaglutide Affordable semaglutide may improve access, reducing complications and hospitalisations globally
